Archives of medical research · 2026
Decreased Natural Killer Cells in Mucormycosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Albarrán-Sánchez Alejandra, Noyola-García Maura E, Borges-López Luis M, Ramírez-Urzúa Geraldine, Ramírez-Rentería Claudia, Arriaga-Pizano Lourdes A, O'Farril-Romanilos Patricia, Sánchez Diana Herrera, Pérez-Pedraza Elsy Estefania, Ferreira-Hermosillo Aldo, López-Cruz Luis Angel, Juárez-Palacios Jesus Emmanuel, Prieto-Chávez Jessica Lakshmi, López-Macías Constantino Iii Roberto
Аннотация
BACKGROUND: Mucormycosis is an invasive fungal infection associated with high morbidity and mortality rates. Previous in vitro studies have demonstrated functional abnormalities in natural killer (NK) cells; however, it remains unclear whether circulating NK cell counts are altered in affected patients.
AIM: To assess baseline NK cell counts and explore their clinical associations in patients with mucormycosis treated at a tertiary referral hospital in Mexico City.
METHODS: We conducted a cross-sectional analytical study of hospitalized patients with active mucormycosis, as confirmed by direct tissue examination and culture, at the Hospital de Especialidades, Centro Médico Nacional Siglo XXI. From 2019-2024, we performed peripheral blood immunophenotyping and obtained sociodemographic, clinical, and biochemical data. Non-parametric tests were used to compare NK cell counts across clinical subgroups.
RESULTS: We included 34 patients (59% male; median age, 59 years). Rhino-orbital-cerebral mucormycosis was the most frequent presentation. The most common comorbidities were diabetes (85.3%), hypertension (64.7%), and chronic kidney disease (8.8%). Poor glycemic control (79.4%), prior corticosteroid use (38.2%), previous COVID-19 infection (26.5%), and solid cancer (5.9%) were the main risk factors. Compared with the reference range patients showed reduced NK cell counts (median 0.11 [IQR, 0.05-0.24] vs. 0.15-0.43 × 10³/µL). NK cell counts were not associated with mortality or prior COVID-19 infection.
CONCLUSIONS: Patients with mucormycosis show decreased circulating NK cell counts, suggesting immune dysregulation. These findings describe a distinct immunologic phenotype rather than a causal or prognostic marker.
AIM: To assess baseline NK cell counts and explore their clinical associations in patients with mucormycosis treated at a tertiary referral hospital in Mexico City.
METHODS: We conducted a cross-sectional analytical study of hospitalized patients with active mucormycosis, as confirmed by direct tissue examination and culture, at the Hospital de Especialidades, Centro Médico Nacional Siglo XXI. From 2019-2024, we performed peripheral blood immunophenotyping and obtained sociodemographic, clinical, and biochemical data. Non-parametric tests were used to compare NK cell counts across clinical subgroups.
RESULTS: We included 34 patients (59% male; median age, 59 years). Rhino-orbital-cerebral mucormycosis was the most frequent presentation. The most common comorbidities were diabetes (85.3%), hypertension (64.7%), and chronic kidney disease (8.8%). Poor glycemic control (79.4%), prior corticosteroid use (38.2%), previous COVID-19 infection (26.5%), and solid cancer (5.9%) were the main risk factors. Compared with the reference range patients showed reduced NK cell counts (median 0.11 [IQR, 0.05-0.24] vs. 0.15-0.43 × 10³/µL). NK cell counts were not associated with mortality or prior COVID-19 infection.
CONCLUSIONS: Patients with mucormycosis show decreased circulating NK cell counts, suggesting immune dysregulation. These findings describe a distinct immunologic phenotype rather than a causal or prognostic marker.